News & Updates
Filter by Specialty:
Bulky tumours in PCNSL tied to high local treatment failure
Systemic and intrathecal therapies are necessary for local control in patients with primary central nervous system lymphoma (PCNSL), but bulky tumours remain a problem, according to a study.
Bulky tumours in PCNSL tied to high local treatment failure
10 Jul 2024
Efgartigimod shows promise in treatment-resistant myasthenia gravis
Use of efgartigimod, a first-in-class investigational antibody fragment targeting the neonatal Fc receptor (FCRN), demonstrates both efficacy and safety in patients with refractory, treatment-resistant generalized myasthenia gravis (MG), as shown in a study presented at EAN 2024.
Efgartigimod shows promise in treatment-resistant myasthenia gravis
09 Jul 2024
Anti-CD20 show promise in multiple sclerosis after alemtuzumab
Treatment with anti-CD20 monoclonal antibodies appears to be a viable option for patients with relapsing-remitting multiple sclerosis (RRMS) who have uncontrolled disease following the use of alemtuzumab therapy, suggests a study presented at EAN 2024.
Anti-CD20 show promise in multiple sclerosis after alemtuzumab
08 Jul 2024
Advanced imaging can identify ischaemic stroke patients for intra-arterial thrombectomy >6 hours from symptom onset
According to a study conducted by the University of Hong Kong (HKU) and Queen Mary Hospital (QMH) since mid-2018, advanced imaging can identify patients with acute ischaemic stroke for intra-arterial thrombectomy even beyond 6 hours from symptom onset.
Advanced imaging can identify ischaemic stroke patients for intra-arterial thrombectomy >6 hours from symptom onset
04 Jul 2024
Rituximab shows promise in management of neuropsychiatric SLE
Treatment with rituximab (RTX) in patients with moderate-to-severe neuropsychiatric (NP) systemic lupus erythematosus (SLE) appears to result in some improvements and to contribute to the use of a much lower steroid dose at 6 months, suggests a study presented at EULAR 2024.